by Gemma Escarré,
Biopharmaceutical firm Spherium Biomed has begun phase-I clinical trials on their product Cilakin to prevent acute kidney injury (AKI) based on more than 10 yearsof research conducted by Dr Alberto Tejedor and Dr Alberto Lázaro at Hospital Gregorio Marañón in Madrid. Spherium acquired the licence in 2015 in order to develop an injectable drug suitable for patients (more than 3 million cases each year in Europe, the United States and Japan).
"Cilakin could become the first standardised preventative treatment for this condition," explains Dr Montserrat Cano, head ofthe project at Spherium. The mortality rate can be up to 70% in patients with acute kidney failure associated with sepsis.
CEO of the company Luis Ruiz-Ávila noted, "We've consolidated our model, which consists in developing biomedical products based on scientific knowledge from universities and research centres anywhere in the world."
Photo: From left to right, the co-founders of the company Luis Ruiz-Ávila, Maribel Bergés and Ramon Bosser - © Spherium Biomed.